ArticleJournal of Alzheimer's disease reports
A multivariate plasma pathology-cognition axis reveals biologically anchored residual cognitive heterogeneity across the Alzheimer's disease clinical spectrum.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Alzheimer's disease (AD) pathology does not fully determine clinical expression, as individuals with similar biomarker-defined burden may show substantial differences in cognition. Characterizing cognitive variation beyond pathological burden may improve understanding of clinical heterogeneity in AD. Objective: To develop a multivariate plasma pathology-cognition framework that derives a pathology-anchored residual phenotype capturing cognitive variation beyond circulating pathological burden and to evaluate its clinical and longitudinal relevance. Methods: We analyzed 868 participants from the Alzheimer's Disease Neuroimaging Initiative with plasma p-tau217, glial fibrillary acidic protein, and neurofilament light chain measurements, cognitive assessments, and clinical characterization. Canonical correlation analysis derived a multivariate plasma pathology index and cognitive composite based on memory and language performance. The residual phenotype was defined as the deviation between observed cognition and cognition expected from plasma pathology burden. Clinical correlates and longitudinal trajectories were evaluated using regression and mixed-effects models. Biological validity was assessed by examining associations with amyloid-β and tau positron emission tomography measures. Results: The first canonical correlation between plasma markers and cognition was significant (r = 0.610, permutation p < 0.001). The plasma pathology index correlated with amyloid-β and tau positron emission tomography measures. The resulting pathology-anchored residual phenotype was associated with clinical diagnosis, education, Conclusions: A plasma pathology-anchored residual phenotype captures clinically meaningful cognitive heterogeneity beyond circulating biomarkers and provides a scalable framework for investigating differential clinical manifestations of AD pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.